126 related articles for article (PubMed ID: 34688123)
1. Evaluation of prognostication scores and proposal for refinement in malignant pleural effusion in Asians.
Wong C; Wing-Cheuk Wong R; Kit-Ying So L; Yin-Chun Yam L
Respir Med; 2021; 189():106650. PubMed ID: 34688123
[TBL] [Abstract][Full Text] [Related]
2. Malignant pleural effusion survival prognostication in an Asian population.
Quek JC; Tan QL; Allen JC; Anantham D
Respirology; 2020 Dec; 25(12):1283-1291. PubMed ID: 32390227
[TBL] [Abstract][Full Text] [Related]
3. An Observational Study Evaluating the Performance of LENT Score in the Selected Population of Malignant Pleural Effusion from Lung Adenocarcinoma in Singapore.
Abisheganaden J; Verma A; Dagaonkar RS; Light RW
Respiration; 2018; 96(4):308-313. PubMed ID: 29945142
[TBL] [Abstract][Full Text] [Related]
4. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score.
Clive AO; Kahan BC; Hooper CE; Bhatnagar R; Morley AJ; Zahan-Evans N; Bintcliffe OJ; Boshuizen RC; Fysh ET; Tobin CL; Medford AR; Harvey JE; van den Heuvel MM; Lee YC; Maskell NA
Thorax; 2014 Dec; 69(12):1098-104. PubMed ID: 25100651
[TBL] [Abstract][Full Text] [Related]
5. Prediction modeling using routine clinical parameters to stratify survival in malignant pleural mesothelioma patients complicated with malignant pleural effusion.
Zhang S; Zhang Y; Feng W; Shi Z; Shi H; Zhang Y
Thorac Cancer; 2021 Dec; 12(24):3304-3309. PubMed ID: 34704370
[TBL] [Abstract][Full Text] [Related]
6. Can LENT Prognostic score (LDH, ECOG performance score, blood neutrophil/lymphocyte ratio, tumor type) change the clinical approach in malignant pleural effusion?
Gayaf M; Anar C; Canbaz M; Doğan Bİ; Erbaycu AE; Güldaval F
Tuberk Toraks; 2021 Jun; 69(2):133-143. PubMed ID: 34256503
[TBL] [Abstract][Full Text] [Related]
7. Breast and Lung Effusion Survival Score Models: Improving Survival Prediction in Patients With Malignant Pleural Effusion and Metastasis.
Molina S; Martinez-Zayas G; Sainz PV; Leung CH; Li L; Grosu HB; Adachi R; Ost DE
Chest; 2021 Sep; 160(3):1075-1094. PubMed ID: 33852918
[TBL] [Abstract][Full Text] [Related]
8. The role of LENT and PROMISE scores in predicting survival in malignant pleural effusion.
Ermin S; Özdogan Y; Batum Ö; Yilmaz U
Lung India; 2022; 39(4):325-330. PubMed ID: 35848663
[TBL] [Abstract][Full Text] [Related]
9. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma.
Verma A; Chopra A; Lee YW; Bharwani LD; Asmat AB; Aneez DB; Akbar FA; Lim AY; Chotirmall SH; Abisheganaden J
Curr Drug Discov Technol; 2016; 13(2):68-76. PubMed ID: 27216707
[TBL] [Abstract][Full Text] [Related]
10. Validating LENT score in malignant pleural effusion.
Alawneh A; Farsakh FA; Smadi M; Samrah S
Future Sci OA; 2024; 10(1):FSO958. PubMed ID: 38817378
[No Abstract] [Full Text] [Related]
11. Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma.
Liu D; Lu Y; Hu Z; Wu N; Nie X; Xia Y; Han Y; Li Q; Zhu G; Bai C
PLoS One; 2014; 9(2):e89946. PubMed ID: 24587142
[TBL] [Abstract][Full Text] [Related]
12. Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.
Yao Y; Peng M; Shen Q; Hu Q; Gong H; Li Q; Zheng Z; Xu B; Li Y; Dong Y
Thorac Cancer; 2019 Feb; 10(2):193-202. PubMed ID: 30565433
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung.
Wang S; Chen H; Zhong J; Qin H; Bai H; Zhao J; Wang J
Lung Cancer; 2019 Sep; 135():116-122. PubMed ID: 31446983
[TBL] [Abstract][Full Text] [Related]
14. Predicting the survival in patients with malignant pleural effusion undergoing indwelling pleural catheter insertion.
Akram MJ; Khalid U; Ashraf MB; Bakar MA; Butt FM; Khan F
Ann Thorac Med; 2020; 15(4):223-229. PubMed ID: 33381237
[TBL] [Abstract][Full Text] [Related]
15. Analysis of EGFR mutation status in malignant pleural effusion and plasma from patients with advanced lung adenocarcinoma.
Son SM; Woo CG; Han HS; Lee KH; Lim YH; Lee OJ
Clin Chem Lab Med; 2020 Aug; 58(9):1547-1555. PubMed ID: 32229655
[TBL] [Abstract][Full Text] [Related]
16. Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients.
Song Z; Wang W; Li M; Liu J; Zhang Y
Lung Cancer; 2019 Oct; 136():23-29. PubMed ID: 31421258
[TBL] [Abstract][Full Text] [Related]
17. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in patients with malignant pleural effusion: Is it possible to predict mortality in patients with good performance status?
Abrao FC; Peixoto RD; de Abreu IR; Janini MC; Viana GG; de Oliveira MC; Younes RN
J Surg Oncol; 2016 Apr; 113(5):570-4. PubMed ID: 26751412
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of a new score using serum alkaline phosphatase and pleural effusion lactate dehydrogenase for patients with malignant pleural effusion.
Shi XY; Yi FS; Wang Z; Qiao X; Zhai K
Thorac Cancer; 2020 Feb; 11(2):320-328. PubMed ID: 31837116
[TBL] [Abstract][Full Text] [Related]
20. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
Tsai TH; Su KY; Wu SG; Chang YL; Luo SC; Jan IS; Yu CJ; Yu SL; Shih JY; Yang PC
Eur Respir J; 2012 Mar; 39(3):677-84. PubMed ID: 21719485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]